[go: up one dir, main page]

ATE308565T1 - Immunogene alk (anaplastic lymphoma kinase) peptide - Google Patents

Immunogene alk (anaplastic lymphoma kinase) peptide

Info

Publication number
ATE308565T1
ATE308565T1 AT02787687T AT02787687T ATE308565T1 AT E308565 T1 ATE308565 T1 AT E308565T1 AT 02787687 T AT02787687 T AT 02787687T AT 02787687 T AT02787687 T AT 02787687T AT E308565 T1 ATE308565 T1 AT E308565T1
Authority
AT
Austria
Prior art keywords
alk
peptides
anaplastic lymphoma
lymphoma kinase
immunogenic
Prior art date
Application number
AT02787687T
Other languages
English (en)
Inventor
Carlo Gambacorti-Passerini
Lorena Passoni
Original Assignee
Ist Naz Stud Cura Dei Tumori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ist Naz Stud Cura Dei Tumori filed Critical Ist Naz Stud Cura Dei Tumori
Application granted granted Critical
Publication of ATE308565T1 publication Critical patent/ATE308565T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4251—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT02787687T 2001-11-15 2002-11-14 Immunogene alk (anaplastic lymphoma kinase) peptide ATE308565T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/008,377 US20030157101A1 (en) 2001-11-15 2001-11-15 Immunogenic ALK peptides
PCT/EP2002/012764 WO2003042243A2 (en) 2001-11-15 2002-11-14 Immunogenic alk (anaplastic lymphoma kinase) peptides

Publications (1)

Publication Number Publication Date
ATE308565T1 true ATE308565T1 (de) 2005-11-15

Family

ID=21731292

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02787687T ATE308565T1 (de) 2001-11-15 2002-11-14 Immunogene alk (anaplastic lymphoma kinase) peptide

Country Status (9)

Country Link
US (1) US20030157101A1 (de)
EP (1) EP1444261B1 (de)
AT (1) ATE308565T1 (de)
AU (1) AU2002352011A1 (de)
CY (1) CY1105357T1 (de)
DE (1) DE60207103T2 (de)
DK (1) DK1444261T3 (de)
ES (1) ES2250727T3 (de)
WO (1) WO2003042243A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4931154B2 (ja) * 2005-02-28 2012-05-16 オンコセラピー・サイエンス株式会社 血管内皮増殖因子受容体１に由来するエピトープ・ペプチドおよびこれらのペプチドを含むワクチン
EP2042191B1 (de) 2007-09-28 2013-01-02 Roberto Chiarle Anaplastische Lymphom-Kinase (ALK) als Onko-Antigen für die Lymphon-Impfung
CA3012764A1 (en) 2016-01-29 2017-08-03 Vedantra Pharmaceuticals, Inc. Alk polypeptides and methods of use thereof
US20230020894A1 (en) * 2019-09-18 2023-01-19 Children's Medical Center Corporation An anaplastic lymphoma kinase (alk) cancer vaccine and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5529925A (en) * 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma

Also Published As

Publication number Publication date
EP1444261B1 (de) 2005-11-02
DE60207103D1 (en) 2005-12-08
CY1105357T1 (el) 2010-03-03
ES2250727T3 (es) 2006-04-16
WO2003042243A2 (en) 2003-05-22
DK1444261T3 (da) 2006-03-20
AU2002352011A1 (en) 2003-05-26
US20030157101A1 (en) 2003-08-21
WO2003042243A3 (en) 2004-03-25
EP1444261A2 (de) 2004-08-11
DE60207103T2 (de) 2006-10-05

Similar Documents

Publication Publication Date Title
AU2003242305A1 (en) Hla-a24-restricted cancer antigen peptide
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
CY1113379T1 (el) Πεπτιδια κdr και εμβολια που τα περιλαμβανουν
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
WO2004067023A3 (en) Survivin-derived peptides and use thereof
HUP0203968A2 (hu) Készítmények és eljárások prosztatarák terápiájára és diagnózisára
DK1468014T3 (da) Sammensætninger og fremgangsmåder til WT1-specifik immunterapi
AU2003256912A1 (en) Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
UA85365C2 (ru) Продукт конъюгирования цитокина для использования в противораковой терапии
AU2003267401A1 (en) Novel mhc ii associated peptides
DE60238044D1 (de) Tumortherapie mit vektoren auf sindbis virus-basis
CY1105179T1 (el) Φαρμακα για την ανοσοθepαπεια κακοηθων ογκων
NO20011537L (no) Chemokin-reseptorpeptidvaksiner for behandling og forebygging av diabetes
DK0889969T3 (da) Rekombinante adenovirale til genterapi af humane tumorer
WO2006023598A3 (en) Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
ATE308565T1 (de) Immunogene alk (anaplastic lymphoma kinase) peptide
WO2003093298A3 (en) Immunogenic peptides
WO2000052045A3 (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
DK1578772T3 (da) Cytokiner og cytokinreceptorer med reduceret immunogenicitet
DK0996636T3 (da) HA-1-antigenet
UY26170A1 (es) Antigeno (c42) asociados a tumores
ATE315406T1 (de) Semi-allogene antitumor-vakzine mit hla-haplo- identischen antigen-präsentierenden zellen
SG148195A1 (en) Plasmids coding for p185neu protein sequence variants and therapeutic uses thereof
TW200607517A (en) Medicinal composition capable of suppressing proliferation or metastasis of tumor cells

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1444261

Country of ref document: EP

REN Ceased due to non-payment of the annual fee